A new and practical synthesis of lumateperone tosylate is developed. The intermediate, ethyl (4aS,3,4,4a,5,indole-2-carboxylate (12), is prepared on kilograms scale in 31% overall yield and >99% ee. (6bR,10aS)-3- 3,6b,7,8,9,10,4':4,5]pyrrolo[1,2,3-de]quinoxaline hydrochloride (16-HCl) is obtained through reductamination reaction, palladium catalyzed cyclization and ester hydrolysis in 60% yield over 3 steps and >98% purity. Lumateperone tosylate is produced on 20 g scale in 65% yield over 2 steps and >99% purity (HPLC).Purification methods of the intermediates and the final product involved in the route are developed.Lumateperone tosylate (1, Scheme 1, Caplyta TM ), developed by Intra-Cellular Therapies, Inc., was approved by the U.S. Food and Drug Administration (FDA) in Dec. 2019, for the treatment of schizophrenia in adults. 1 The efficacy of lumateperone could be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors. 2 With regard to the synthesis of lumateperone (2), a couple of routes had been reported, as shown in Scheme 1. As early as 2000, lumateperone (2) was prepared as the racemic form. 3 3,4-Dihydroquinoxalin-2(1H)-one (3) was used as the starting material, the nitrosation product 4 was condensed with ethyl 4-oxopiperidine-1-carboxylate (5) to give the 1H-pyrrolo[1,2,3-de]quinoxalin-2(3H)-one 6 in 35% yield over 2 steps, which was hydrogenated by NaBH3CN in TFA to give the 5,6-dihydro-1H-pyrrolo[1,2,3-de]quinoxalin-2(3H)-one 7 in 89% yield.